

Pemetrexed:

Alimta®; Pemfexy™; Pemetrexed Ψ (Intravenous)

Document Number: IC-0007

Last Review Date: 09/05/2023

Date of Origin: 07/20/2010

Dates Reviewed: 09/2010, 12/2010, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 12/2020, 03/2021, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 12/2022, 03/2023, 07/2023, 09/2023

I. Length of Authorization ^{15,26,28-30}

Coverage will be provided for 6 months and may be renewed, unless otherwise specified.

- Thymomas/Thymic Carcinoma: Coverage will be provided for six (6) cycles and may NOT be renewed.
- MPeM and MPM in combination with bevacizumab AND either cisplatin or carboplatin: Coverage will be provided for six (6) cycles and may NOT be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Alimta 100 mg powder for injection in a single-use vial: 4 vials every 21 days
- Alimta 500 mg powder for injection in a single-use vial: 4 vials every 21 days
- Pemfexy 500 mg solution for injection in a multi-dose vial: 4 vials every 21 days
- Pemetrexed 750 mg powder for injection: 2 vials every 21 days
- Pemetrexed 1000 mg powder for injection: 2 vials every 21 days
- Pemetrexed 100 mg/4 mL solution for injection: 4 vials every 21 days
- Pemetrexed 500 mg/20 mL solution for injection: 4 vials every 21 days
- Pemetrexed 850 mg/34 mL solution for injection: 2 vials every 21 days
- Pemetrexed 1000 mg/40 mL solution for injection: 2 vials every 21 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- Pemfexy (500 mg MDV):
 - Primary CNS Lymphoma, Cervical Cancer, and Ovarian Cancer: 225 billable units every 21 days
 - Leptomeningeal Metastases from NSCLC: 5 billable units every 28 days

- All other indications: 125 billable units every 21 days
- All other manufacturers (100 mg, 500 mg, 750 mg, 850 mg, and 1000 mg SDV):
 - Primary CNS Lymphoma, Cervical Cancer, and Ovarian Cancer: 230 billable units every 21 days
 - Leptomeningeal Metastases from NSCLC: 10 billable units every 28 days
 - All other indications: 130 billable units every 21 days

III. Initial Approval Criteria ^{1,2}

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Central Nervous System (CNS) Cancers ‡ ^{3,16,27,33}

- Used as a single agent; **AND**
 - Patient has Primary Central Nervous System (CNS) Lymphoma; **AND**
 - Used as induction therapy in patients unsuitable for or intolerant to high-dose methotrexate (MTX); **OR**
 - Used for relapsed or refractory disease; **OR**
 - Patient has leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer (NSCLC); **AND**
 - Used as primary treatment in patients with good risk status (i.e., KPS \geq 60, no major neurologic deficits, minimal systemic disease, and reasonable systemic treatment options if needed); **OR**
 - Used as maintenance treatment in patients with negative cerebrospinal fluid (CSF) cytology or in clinically stable patients with persistently positive CSF cytology

Cervical Cancer ‡ ³

- Used as subsequent therapy for recurrent or metastatic disease; **AND**
- Patient has squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; **AND**
- Used as a single agent

Malignant Peritoneal* Mesothelioma (MPeM) ‡ ^{3,29}

- Used as adjuvant therapy; **AND**
 - Patient has diffuse unicavitary disease with epithelioid histology; **AND**
 - Patient has surgical/pathologic high-risk features** and no neoadjuvant therapy was given; **AND**
 - Used as a single agent OR in combination with cisplatin or carboplatin (if cisplatin ineligible); **OR**
- Used as first-line therapy; **AND**

- Used in combination with bevacizumab AND either cisplatin or carboplatin (if cisplatin ineligible) for unresectable diffuse or recurrent disease; **OR**
- Used as a single agent OR in combination with cisplatin or carboplatin (if cisplatin ineligible) for diffuse or recurrent disease; **OR**
- Used as subsequent therapy; **AND**
 - Used as a single agent OR in combination with cisplatin or carboplatin (if cisplatin ineligible), with or without bevacizumab; **AND**
 - Immunotherapy was administered as first-line treatment; **OR**
 - Used as a rechallenge if pemetrexed-based treatment was administered first-line with good response

** Note: May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma.*

**** High-risk features include Ki-67 >9%, nodal metastasis, high tumor burden (Peritoneal Cancer Index [PCI] >17), completeness of cytoreduction (CC) score >1, biphasic disease, or bicavitary disease**

Malignant Pleural* Mesothelioma (MPM) † ‡ Φ^{1-6,10,26}

- Used as induction therapy; **AND**
 - Used in combination with cisplatin or carboplatin (if cisplatin ineligible) in patients with clinical stage I-IIIa disease and epithelioid histology; **OR**
- Used as first-line therapy; **AND**
 - Used in combination with bevacizumab AND either cisplatin or carboplatin (if cisplatin ineligible); **OR**
 - Used as a single agent OR in combination with cisplatin or carboplatin (if cisplatin ineligible); **OR**
- Used as subsequent therapy; **AND**
 - Used as a single agent OR in combination with cisplatin or carboplatin (if cisplatin ineligible), with or without bevacizumab; **AND**
 - Immunotherapy was administered as first-line treatment; **OR**
 - Used as a rechallenge if pemetrexed-based treatment was administered first-line with good response

** Note: May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma.*

Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) † ‡^{1-3,7-9,11,12,28,30}

- Used in combination with a carboplatin or cisplatin-containing regimen; **OR**
- Used in combination with bevacizumab, pembrolizumab, cemiplimab, or durvalumab for continuation maintenance therapy if previously used first-line and patient achieved a tumor response or stable disease following initial therapy; **OR**
- Used as a single agent; **AND**

- Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
 - Used as first-line therapy for tumors that are negative for actionable molecular biomarkers*; **OR**
 - Used as first-line therapy for EGFR exon 20 mutation, KRAS G12C mutation, BRAF V600E-mutation, NTRK1/2/3 gene fusion, MET exon 14 skipping mutation, RET rearrangement, or ERBB2 (HER2) mutation positive tumors; **OR**
 - Used as subsequent therapy; **OR**
 - Used as continuation or switch maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy

** Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2). If there is insufficient tissue to allow testing for all of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2), repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

Thymomas/Thymic Carcinoma ‡^{3,14,15,25}

- Used as a single agent; **AND**
 - Used as first-line therapy or postoperative treatment in patients who are unable to tolerate first-line combination regimens; **OR**
 - Used as second-line therapy for unresectable or metastatic disease

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer ‡^{3,13,24}

- Used as a single agent; **AND**
 - Patient has recurrent or persistent Grade 1 Endometrioid Carcinoma, Carcinosarcoma (Malignant Mixed Müllerian Tumors), Mucinous Carcinoma of the Ovary, Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer, or Clear Cell Carcinoma of the Ovary; **AND**
 - Patient is not experiencing an immediate biochemical relapse (i.e., rising CA-125 without radiographic evidence of disease); **OR**
 - Patient has recurrent Low-Grade Serous Carcinoma

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ☐ Orphan Drug

| § Genomic Aberration/Mutational Driver Targeted Therapies (Note: not all inclusive, refer to guidelines for appropriate use) | | | | |
|---|--|--|--|--|
| Sensitizing EGFR mutation-positive tumors | ALK rearrangement-positive tumors | ROS1 rearrangement-positive tumors | BRAF V600E-mutation positive tumors | NTRK1/2/3 gene fusion positive tumors |
| <ul style="list-style-type: none"> – Afatinib – Erlotinib – Dacomitinib | <ul style="list-style-type: none"> – Alectinib – Brigatinib – Ceritinib | <ul style="list-style-type: none"> – Ceritinib – Crizotinib – Entrectinib | <ul style="list-style-type: none"> – Dabrafenib ± trametinib – Vemurafenib | <ul style="list-style-type: none"> – Larotrectinib – Entrectinib |

PEMETREXED (Alimta®; Pemfexy™; Pemetrexed Ψ)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2023, Magellan Rx Management

MagellanRx
MANAGEMENT™

| | | | | |
|--|---|--|--|--|
| <ul style="list-style-type: none"> – Gefitinib – Osimertinib – Amivantamab (exon-20 insertion) – Mobocertinib (exon-20 insertion) | <ul style="list-style-type: none"> – Crizotinib – Lorlatinib | <ul style="list-style-type: none"> – Lorlatinib | | |
| PD-L1 tumor expression $\geq 1\%$ | <i>MET</i> exon-14 skipping mutations | <i>RET</i> rearrangement-positive tumors | <i>KRAS G12C</i> mutation positive tumors | <i>ERBB2 (HER2)</i> mutation positive tumors |
| <ul style="list-style-type: none"> – Pembrolizumab – Atezolizumab – Nivolumab + ipilimumab – Cemiplimab – Tremelimumab + durvalumab | <ul style="list-style-type: none"> – Capmatinib – Crizotinib – Tepotinib | <ul style="list-style-type: none"> – Selpercatinib – Cabozantinib – Pralsetinib | <ul style="list-style-type: none"> – Sotorasib – Adagrasib | <ul style="list-style-type: none"> – Fam-trastuzumab deruxtecan-nxki – Ado-trastuzumab emtansine |

IV. Renewal Criteria ^{1,2}

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: myelosuppression (e.g., neutropenia, febrile neutropenia, thrombocytopenia, anemia), renal toxicity ($\text{CrCl} < 45 \text{ mL/min}$), bullous and exfoliative skin toxicity (e.g., Stevens-Johnson Syndrome/Toxic epidermal necrolysis), interstitial pneumonitis, radiation recall, etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**

MPeM and MPM ^{26,29}

- Coverage may NOT be renewed when used in combination with bevacizumab AND either cisplatin or carboplatin

Thymomas/Thymic Carcinoma ¹⁵

- Coverage may NOT be renewed

V. Dosage/Administration ^{1,2,10,13,15,16,26,28-33}

| Indication | Dose |
|--------------------|---|
| Non-Squamous NSCLC | Administer up to 500 mg/m ² intravenously every 21 days |
| MPM, MPeM | Administer 500 mg/m ² intravenously every 21 days <ul style="list-style-type: none"> – For 6 cycles only when used in combination with bevacizumab AND either cisplatin or carboplatin – All others until disease progression or unacceptable toxicity |

| | |
|--|---|
| Ovarian Cancer, Cervical Cancer | Administer 900 mg/m ² intravenously every 21 days, until disease progression or unacceptable toxicity |
| Thymomas/Thymic Carcinoma | Administer 500 mg/m ² intravenously every 21 days for a maximum of 6 cycles or until disease progression or unacceptable toxicity |
| CNS Cancers | <u>Primary CNS Lymphoma</u> Administer 900 mg/m ² intravenously every 21 days, until disease progression or unacceptable toxicity <u>Leptomeningeal metastases from EGFR mutation-positive NSCLC</u> Administer 50 mg intrathecally every 28 days, until disease progression or unacceptable toxicity |
| <ul style="list-style-type: none"> • Supplement with oral folic acid and intramuscular vitamin B₁₂. • Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration in patients with CrCl <80 mL/min. • Do not administer in patients with CrCl <45 mL/min. | |

VI. Billing Code/Availability Information

| Product Formulation | Drug | Manufacturer | Type | HCPCS Code | NDC |
|---|--|--------------|---------|------------|---------------|
| Pemetrexed Disodium Lyophilisate for injection | Alimta 100 mg powder for inj. SDV * | Lilly | Brand | J9305 | 00002-7640-xx |
| | Alimta 500 mg powder for inj. SDV * | | | | 00002-7623-xx |
| | Pemetrexed 100 mg powder for inj. SDV ψ | Hospira | Brand | J9294 | 00409-1060-xx |
| | Pemetrexed 500 mg powder for inj. SDV ψ | | | | 00409-1061-xx |
| | Pemetrexed 750 mg powder for inj. SDV * | N/A | Generic | J9305 | N/A |
| | Pemetrexed 1000 mg powder for inj. SDV * | | | | |
| | Pemetrexed 100 mg powder for inj. SDV ψ | BluePoint | Brand | J9322 | 68001-0543-xx |
| | Pemetrexed 500 mg powder for inj. SDV ψ | | | | 68001-0544-xx |
| | Pemetrexed 750 mg powder for inj. SDV ψ | | | | 68001-0545-xx |
| Pemetrexed 1000 mg powder for inj. SDV ψ | 68001-0546-xx | | | | |
| Pemetrexed Disodium Solution for injection | Pemetrexed 100 mg/4 mL inj. SDV ψ | Sandoz | Brand | J9297 | 00781-3518-xx |
| | | Accord | Brand | J9296 | 16729-0522-xx |
| | | Hospira | Brand | J9294 | 00409-1045-xx |
| | Pemetrexed 500 mg/20 mL inj. SDV ψ | Sandoz | Brand | J9297 | 00781-3519-xx |
| | | Accord | Brand | J9296 | 16729-0522-xx |
| | | Hospira | Brand | J9294 | 00409-2188-xx |
| | Pemetrexed 850 mg/34mL inj. SDV ψ | Accord | Brand | J9296 | 16729-0522-xx |
| | Pemetrexed 1000 mg/40 mL inj. SDV ψ | Accord | Brand | J9296 | 16729-0522-xx |
| | | Hospira | Brand | J9294 | 00409-3532-xx |
| Pemetrexed Solution for injection | Pemfexy 500 mg/20 mL inj. MDV | Eagle | Brand | J9304 | 42367-0531-xx |
| | Pemetrexed 100 mg/4mL inj. SDV ψ | Teva | Brand | J9314 | 00480-4516-xx |
| | Pemetrexed 500 mg/20 mL inj. SDV ψ | Teva | Brand | J9314 | 00480-4514-xx |
| | Pemetrexed 1000 mg/40 mL inj. SDV ψ | Teva | Brand | J9314 | 00480-4515-xx |
| Pemetrexed Ditromethamine for injection | Pemetrexed 100 mg powder for inj. SDV ψ | Hospira | Brand | J9323 | 00409-1060-xx |
| | Pemetrexed 500 mg powder for inj. SDV ψ | | | | 00409-1061-xx |
| *Multiple manufacturers produce ANDA generics | | | | | |
| ψ Designated products approved by the FDA as a 505(b)(2) NDA of the innovator product. These products are not rated as therapeutically equivalent to their reference listed drug in the Food and Drug Administration's (FDA) Orange Book and are therefore considered single source products based on the statutory definition of "single source drug" in section 1847A(c)(6) of the Act. For a complete list of all approved 505(b)(2) NDA products please reference the latest edition of the Orange Book: <u>Approved Drug Products with Therapeutic Equivalence Evaluations / Orange Book / FDA</u> | | | | | |
| J9294 – Injection, pemetrexed (hospira) not therapeutically equivalent to J9305, 10 mg | | | | | |

PEMETREXED (Alimta®; Pemfexy™; Pemetrexed ψ)
Prior Auth Criteria

J9296 – Injection, pemetrexed (accord) not therapeutically equivalent to J9305, 10 mg
 J9297 – Injection, pemetrexed (sandoz), not therapeutically equivalent to J9305, 10 mg
 J9304 – Injection, pemetrexed (pemfexy), 10 mg
 J9305 – Injection, pemetrexed, not otherwise specified, 10 mg
 J9314 – Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg
 J9322 – Injection, pemetrexed (bluepoint) not therapeutically equivalent to J9305, 10 mg
 J9323 – Injection, pemetrexed ditromethamine, 10 mg
 J9999 – Injection, pemetrexed various (shipla, etc.), 10 mg

VII. References

1. Alimta [package insert]. Indianapolis, IN; Eli Lilly; August 2022. Accessed August 2023.
2. Pemfexy [package insert]. Woodcliff Lake, NJ; Eagle Pharmaceuticals, Inc; December 2022. Accessed August 2023.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for pemetrexed. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
4. Castagneto B, Botta M, Aitini E, et al, “Phase II Study of Pemetrexed in Combination With Carboplatin in Patients With Malignant Pleural Mesothelioma (MPM),” *Ann Oncol*, 2008, 19(2):370-3.
5. Ceresoli GL, Zucali PA, Favaretto AG, et al, “Phase II Study of Pemetrexed plus Carboplatin in Malignant Pleural Mesothelioma,” *J Clin Oncol*, 2006, 24(9):1443-8.
6. Taylor P, Castagneto B, Dark G, et al, “Single-Agent Pemetrexed for Chemo-naïve and Pretreated Patients With Malignant Pleural Mesothelioma: Results of an International Expanded Access Program,” *J Thorac Oncol*, 2008, 3(7):764-71
7. Ciuleanu T, Brodowicz T, Zielinski C, et al, “Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study,” *Lancet*, 2009, 374(9699):1432-40.
8. Grønberg BH, Bremnes RM, Fløtten O, et al, “Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer,” *J Clin Oncol*, 2009, 27(19):3217-24.
9. Hanna N, Shepherd FA, Fossella FV, et al, “Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy,” *J Clin Oncol*, 2004, 22(9):1589-97.
10. Jassem J, Ramlau R, Santoro A, et al, “Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma,” *J Clin Oncol*, 2008, 26(10):1698-704.

11. Scagliotti GV, Parikh P, von Pawel J, et al. "Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer," *J Clin Oncol*, 2008, 26(21):3543-51.
12. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol*. 2016;17(11):1497-1508.
13. Miller DS, Blessing JA, Krasner CN, et al. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. *J Clin Oncol*, 2009, 27(16):2686-91.
14. Liang Y, Padda SK, Riess JW, et al. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. *Lung Cancer*. 2015 Jan;87(1):34-8.
15. Gbolahan OB, Porter RF, Salter JT, et al. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. *J Thorac Oncol*. 2018 Dec;13(12):1940-1948.
16. Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. *Cancer*. 2012 Aug 1;118(15):3743-8.
17. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract*. 2018 Mar;14(3):e130-e136.
18. Hematology/Oncology Pharmacy Association (2019). Intravenous Cancer Drug Waste Issue Brief. Retrieved from http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug_Waste_2019.pdf
19. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ*. 2016 Feb 29;352:i788.
20. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005.
21. Wu YL, Lu S, Cheng Y, et al. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. *Lung Cancer*. 2014;85(3):401-407. doi:10.1016/j.lungcan.2014.07.007.
22. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3.
23. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol*. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136.

24. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
25. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thymomas and Thymic Carcinomas Version 1.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
26. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Mesothelioma: Pleural Version 1.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
27. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers Version 1.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
28. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer Version 3.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
29. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Mesothelioma: Peritoneal Version 2.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2023.
30. Forde P, Spicer J, Provencio M, et.al. Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIa) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Res (2021) 81 (13_Supplement): CT003.<https://doi.org/10.1158/1538-7445.AM2021-CT003>.

31. Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol*. 2008 Jul;110(1):65-70. doi: 10.1016/j.ygyno.2008.03.009.
32. Zalcmán G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6.
33. Fan C, Zhao Q, Li L, et al. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). *J Thorac Oncol*. 2021 Aug;16(8):1359-1368. doi: 10.1016/j.jtho.2021.04.018.

Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description |
|--------|---|
| C33 | Malignant neoplasm of trachea |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus or lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C37 | Malignant neoplasm of thymus |
| C45.0 | Mesothelioma of pleura |
| C45.1 | Mesothelioma of peritoneum |
| C45.2 | Mesothelioma of pericardium |

PEMETREXED (Alimta®; Pemfexy™; Pemetrexed Ψ)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2023, Magellan Rx Management

| ICD-10 | ICD-10 Description |
|--------|---|
| C45.7 | Mesothelioma of other sites |
| C45.9 | Mesothelioma, unspecified |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C57.10 | Malignant neoplasm of unspecified broad ligament |
| C57.11 | Malignant neoplasm of right broad ligament |
| C57.12 | Malignant neoplasm of left broad ligament |
| C57.20 | Malignant neoplasm of unspecified round ligament |
| C57.21 | Malignant neoplasm of right round ligament |
| C57.22 | Malignant neoplasm of left round ligament |
| C57.3 | Malignant neoplasm of parametrium |
| C57.4 | Malignant neoplasm of uterine adnexa, unspecified |
| C57.7 | Malignant neoplasm of other specified female genital organs |
| C57.8 | Malignant neoplasm of overlapping sites of female genital organs |
| C57.9 | Malignant neoplasm of female genital organ, unspecified |
| C79.32 | Secondary malignant neoplasm of cerebral meninges |
| C83.30 | Diffuse large B-cell lymphoma unspecified site |
| C83.39 | Diffuse large B-cell lymphoma extranodal and solid organ sites |
| C83.80 | Other non-follicular lymphoma, unspecified site |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites |
| C85.89 | Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites |
| C85.99 | Non-Hodgkin's lymphoma extranodal and solid organ sites |

PEMETREXED (Alimta®; Pemfexy™; Pemetrexed Ψ)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2023, Magellan Rx Management

| ICD-10 | ICD-10 Description |
|---------|---|
| D15.0 | Benign neoplasm of thymus |
| D19.1 | Benign neoplasm of mesothelial tissue of peritoneum |
| D38.4 | Neoplasm of uncertain behavior of thymus |
| Z85.118 | Personal history of other malignant neoplasm of bronchus and lung |
| Z85.238 | Personal history of other malignant neoplasm of thymus |
| Z85.43 | Personal history of malignant neoplasm of ovary |

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions | | |
|---|---|---|
| Jurisdiction | Applicable State/US Territory | Contractor |
| E (1) | CA, HI, NV, AS, GU, CNMI | Noridian Healthcare Solutions, LLC |
| F (2 & 3) | AK, WA, OR, ID, ND, SD, MT, WY, UT, | Noridian Healthcare Solutions, LLC |
| 5 | KS, NE, IA, MO | Wisconsin Physicians Service Insurance Corp |
| 6 | MN, WI, IL | National Government Services, Inc. (NGS) |
| H (4 & 7) | LA, AR, MS, TX, OK, CO, NM | Novitas Solutions, Inc. |
| 8 | MI, IN | Wisconsin Physicians Service Insurance Corp |
| N (9) | FL, PR, VI | First Coast Service Options, Inc. |
| J (10) | TN, GA, AL | Palmetto GBA, LLC |
| M (11) | NC, SC, WV, VA (excluding below) | Palmetto GBA, LLC |
| L (12) | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc. |
| K (13 & 14) | NY, CT, MA, RI, VT, ME, NH | National Government Services, Inc. (NGS) |
| 15 | KY, OH | CGS Administrators, LLC |

PreferredOne Community Health Plan Nondiscrimination Notice

PreferredOne Community Health Plan (“PCHP”) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PCHP:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist
PreferredOne Community Health Plan
PO Box 59052
Minneapolis, MN 55459-0052
Phone: 1.800.940.5049 (TTY: 763.847.4013)
Fax: 763.847.4010
customerservice@preferredone.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, taiaajiila qarqaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

ໂບດຊາບ: ຖ້າວ່າທ່ານເວົ້າພາສາລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສຍຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ፡ የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያግዝዎት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (መስማት ለተሳናቸው፡ 763.847.4013) .

ဟ်သုာ်ဟ်သး- နမာ်ကတိ၊ ကညီ ကိာ်အယံ၊ နမာ် ကိာ်အတၢ်မၤစၢၤလၢ တလၢာ်ဘၣ်လၢာ်စၢၤ နီတမံၤဘၣ်သန့လီၤ. ကိံး 1.800.940.5049 (TTY: 763.847.4013).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតល្បួល គឺអាចមានសំរាប់បំរើអ្នក។ ចរ ទូរស័ព្ទ 1.800.940.5049 (TTY: 763.847.4013)។

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013), 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).

PreferredOne Insurance Company Nondiscrimination Notice

PreferredOne Insurance Company ("PIC") complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PIC:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist
PreferredOne Insurance Company
PO Box 59212
Minneapolis, MN 55459-0212
Phone: 1.800.940.5049 (TTY: 763.847.4013)
Fax: 763.847.4010
customerservice@preferredone.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

បំពេញ: ប្រសិនបើ អ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያገኙበት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (ማስማት ለተሳናቸው: 763.847.4013) .

ဟံသာဝတီ: နမူနာတို့ ကညီ ကျိအသိ, နမူနာ ကျိအတိအကျတို့ တလက်ကွက်လက်စွာ နှိတ်မိသည့်သို့လိ။ ကိ: 1.800.940.5049 (TTY: 763.847.4013).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013). 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).